28.6 F
New York
Monday, March 8, 2021

Charles River Laboratories [NYSE: CRL] To Purchase Cognate Bioservices For $875

Must read

Fathom [NASDAQ: FTHM] Announces Purchase Of Real Estate Brokerage Business Of Red Barn

Fathom Holdings Inc. revealed that the company has purchased the residential real estate brokerage business of Red Barn Real Estate. Additionally, The Real...

Neilsen [NYSE: NLSN] Reports Completion Of The Divestiture Of Global Connect Business

Nielsen Holdings plc revealed that the company has finished the recently reported sale of NielsenIQ to associates of Advent International, in collaboration with...

Chipotle [NYSE: CMG] Collaborates With e.l.f [NYSE: ELF] To Launch Limited-Edition Makeup Collection

Chipotle and e.l.f. beauty is collaborating on March 10 to dispatch the limited edition e.l.f. x Chipotle collection. e.l.f's devotion to cruelty-free...

Jabil Healthcare [NYSE: JBL] Announces Strategic Partnership With E3D

Jabil Healthcare, a subsidiary of Jabil Inc. , revealed that the company has inked a partnership contract with E3D.  It is a worldwide drug...

Charles River Laboratories International, Inc. [NYSE: CRL] revealed that the company has entered into a contract to purchase Cognate BioServices, Inc. for around $875 million in cash. The transaction is subject to customary closing conditions.  

James C. Cultivate, CEO of CRL, stated, “Cognate BioServices presents a novel chance to venture into a high-development, value-added area of the CDMO market. Moreover, It aids us to improve our capacity to address our customers’ needs in arising regions of scientific advancement.”

He further added,” This purchase will be an outstanding key fit, adding to our thorough set-up of early-phase study. It will aid in producing support solutions and empowering us to accomplish our objective of building up a solitary scientific partner to furnish biopharmaceutical customers. So that we can provide clients with an incorporated solution to aid enhancing their cell and gene treatment programs.”

Cognate is a cell and gene therapy CDMo that offers a variety of cell therapy solutions. The transaction will create CRL as a sole partner for cell and gene treatment. Furthermore, CRL will be able to provide the customers with integrated solutions from basic research through GCMP creation. Cognate has broad experience creating different cell types and advances utilized in cell immunotherapy and immuno-oncology.

More articles

Latest article

XpresSpa Group [NASDAQ: XSPA] Inked An Agreement With The Port Of Seattle For A Covid-19 Testing Facility

XpresSpa Group, Inc. a wellbeing and health organization, reported that it has entered into an agreement with the Port of Seattle. The contract...

Zepp Health [NYSE: ZEPP] Announces Expanded Collaboration With Rouumtech

Zepp Health Corp. revealed that the company has expanded its collaboration with Rouumtech Co Ltd.  The contract initially expanded to reach to private label...

Netflix [NASDAQ: NFLX] Rolls Out Fast Laughs Featuring Comedy Bits

Netflix, In revealed through its newsroom the addition of a new feature on its mobile app. The Fast laugh is the new feature...

AT&T [NYSE: T] Enters Into A Contract To Divest Its Government Solution Business

AT&T announced that the company inked an agreement to divest its Government Solution Business (GSI). Tyto Athene will purchase the government solution including...

Sino-Global [NASDAQ: SINO] Announces The Execution Of Purchase Agreement Of 2783 Digital Currency Operating Server

Sino-Global Shipping America reported that the company is going to process the execution of the purchase agreement. The company purchased 2783 digital currency...

Commercial Vehicle Group [NASDAQ: CVGI] To Collaborate With Xos Inc

Commercial Vehicle Group revealed that the company entered into a collaboration with Xos, Inc. Furthermore, Xos is a leading commercial electric vehicle manufacturer....

Upland Software [NASDAQ: UPLD] Announces The Acquisition Of BlueVenn

Upland Software, Inc. revealed that the company has purchased BlueVenn. It is a cloud-based client data platform(CDP). With BlueVenn, Upland clients can now...

Columbus McKinnon [NASDAQ: CMCO] Inks An Agreement To Purchase Dorner

Columbus McKinnon Corporation today reported that the Company has executed an authoritative consent to secure Dorner Manufacturing Corporation. Dorer is an automation solution...